

Pandemic Influenza Preparedness Framework

Partnership Contribution High-Level Implementation Plan I.
Final Report 2014–2017



Pandemic Influenza Preparedness Framework

Partnership Contribution High-Level Implementation Plan I.
Final Report 2014–2017

WHO/WHE/IHM/PIP/2018.3

© **World Health Organization 2018**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Pandemic Influenza Preparedness Framework: Partnership Contribution High-Level Implementation Plan I. Final report 2014–2017. Geneva: World Health Organization; 2018 (WHO/WHE/IHM/PIP/2018.3). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in France

Contents

Foreword	v
Acknowledgements	vi
Acronyms and abbreviations	vii
Executive summary	viii
The PIP Framework: working together for a safer tomorrow	1
The Partnership Contribution	3
Implementing the Partnership Contribution for global progress	6
Impact across areas of work	11
Laboratory & surveillance	11
Burden of disease	19
Regulatory capacity building	25
Risk communications	31
Planning for deployment	37
Laboratory & surveillance capacity building: regions and countries	43
African Region	45
Region of the Americas	55
Eastern Mediterranean Region	65
European Region	75
South-East Asia Region	83
Western Pacific Region	91
What's next?	99
Endnotes	101
Annexes	103
Annex A: Financial report	10
Annex B: Target countries by area of work	11
Annex C: Output indicator results by area of work	11
Annex D: Laboratory & surveillance capacity indicator results	119
Annex E: Definitions for the laboratory & surveillance capacity indicators	121

Foreword

Few events have marked humanity as gravely as the influenza pandemic of 1918. With an estimated 50–100 million deaths, it remains one of the deadliest public health events on record.

Our highly interconnected world allows pathogens to spread at lightning speed, increasing the urgency to ensure that all countries are prepared to respond to an infectious disease outbreak wherever it may emerge. The World Health Organization (WHO) works to ensure that all countries, irrespective of their income or development status, have equitable access to the medical and other counter-measures necessary to respond to pandemics.

It is for these reasons that the Pandemic Influenza Preparedness (PIP) Framework holds such importance for public health: it shows that nations can come together and solve the most difficult issues through innovative solutions; that countries will undertake the work needed to strengthen their preparedness capacities; and that partners – public, private and nongovernmental – will sustain their commitment to achieving the highest level of preparedness so that our future global response is founded on solidarity and equity.

I am deeply grateful to all PIP Framework partners that have demonstrated their sustained commitment to this goal. I look forward to continuing this important work in the same spirit of partnership and solidarity.



.....

Tedros Adhanom Ghebreyesus,
WHO Director-General

.....



Acknowledgements

WHO thanks all stakeholders that contributed to the successful implementation of the Framework in the past four years.

This includes Member States, the Global Influenza Surveillance and Response System (GISRS), the PIP Advisory Group, influenza vaccine, diagnostic and pharmaceutical manufacturers (Industry), civil society and other organizations. WHO is thankful for the support of the GISRS network, including WHO Collaborating Centres for Influenza (CCs), WHO Essential Regulatory Laboratories (ERLs), WHO H5 Reference Laboratories, and National Influenza Centres (NICs).

We are deeply grateful to Industry and Industry Associations for their support over this time, notably through the payment of the annual Partnership Contribution that funded implementation.

We thank implementing units at WHO country offices, regional offices, and headquarters for facilitating implementation and supporting preparation of this final report.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_25493

